Trial Profile
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 28 Dec 2021 Planned End Date changed from 1 Nov 2022 to 1 Oct 2022.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology